Current Report Filing (8-k)
January 03 2013 - 5:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 3, 2013
BIOMIMETIC THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
000-51934
|
|
62-1786244
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
389 Nichol Mill Lane, Franklin, Tennessee 37067
(Address of Principal Executive Offices) (Zip Code)
(615) 844-1280
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
þ
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
BioMimetic Therapeutics, Inc. issued a press release on January 3, 2013 announcing that it has initiated
enrollment in a Phase II clinical trial to assess the safety and efficacy of Augment
Chronic Tendinopathy as a
treatment for lateral epicondylitis, commonly known as tennis elbow. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
99.1
|
|
Press Release of BioMimetic Therapeutics, Inc., dated January 3, 2013 announcing the Phase II clinical trial for Augment
Chronic Tendinopathy.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
BIOMIMETIC THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ Samuel E. Lynch
|
Name:
|
|
Samuel E. Lynch
|
Title:
|
|
President and Chief Executive Officer
|
Date: January 3, 2013
Biomimetic Therapeutics, Inc. (MM) (NASDAQ:BMTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biomimetic Therapeutics, Inc. (MM) (NASDAQ:BMTI)
Historical Stock Chart
From Sep 2023 to Sep 2024